AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States.
Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.
The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Country | United States |
IPO Date | Oct 9, 2012 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 32 |
CEO | Joseph P. Hagan M.B.A. |
Contact Details
Address: 4224 Campus Point Court San Diego, California United States | |
Website | https://www.regulusrx.com |
Stock Details
Ticker Symbol | RGLS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001505512 |
CUSIP Number | 75915K309 |
ISIN Number | US75915K3095 |
Employer ID | 26-4738379 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Joseph P. Hagan M.B.A. | Chief Executive Officer & Director |
Crispina Calsada CPA | Chief Financial Officer |
Christopher Ray Aker J.D. | Senior Vice President, General Counsel & Corporate Secretary |
Daniel J. Penksa | Vice President of Finance & Controller |
Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations |
Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research & Development and Director |
Dr. Rekha Garg M.D., M.S. | Chief Medical Officer |
Edmund Lee Ph.D. | Vice President of Translational Medicine |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 10, 2025 | 4 | Filing |
Jan 10, 2025 | 4 | Filing |
Jan 10, 2025 | 4 | Filing |
Jan 10, 2025 | 4 | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Nov 07, 2024 | 10-Q | Quarterly Report |